{"nctId":"NCT01374971","briefTitle":"Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)","startDateStruct":{"date":"2011-09"},"conditions":["Rheumatoid Arthritis"],"count":12,"armGroups":[{"label":"Certolizumab Pegol (CZP)","type":"OTHER","interventionNames":["Drug: Certolizumab Pegol (CZP)","Procedure: Arthroscopic synovial tissue biopsy"]}],"interventions":[{"name":"Certolizumab Pegol (CZP)","otherNames":["Brand Name: Cimzia","UCB product: Certolizumab Pegol (CDP870)","Pre-filled syringe: NDC50474-710-79"]},{"name":"Arthroscopic synovial tissue biopsy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed and dated informed consent document\n* Subjects must be at least 18 years of age or older\n* Subject must be willing and able to comply with scheduled visits, arthroscopy, laboratory tests, and other procedures\n* Diagnosis of RA based on American College of Rheumatology (ACR) 1987 Revised Criteria\n* Active disease at screening visit\n* Methotrexate taken continuously for at least 12 weeks at a stable dosage\n* Sexually active women of child-bearing potential and men whose partners are women of child-bearing potential are required to use adequate contraceptive methods during participation on this trial\n* Treatment with non-steroidal anti-inflammatory drugs (NSAIDS)and oral corticosteroids (less than or equal to 10 mg/day prednisone or equivalent)is accepted\n\nExclusion Criteria:\n\n* Diagnosis of any other inflammatory arthritis\n* History of infected joint prosthesis that is still in situ\n* History of allergy to local anesthetic agents\n* Pregnant or lactating women\n* Current or recent history of uncontrolled clinically significant conditions(e.g..,kidney disease, liver disease, class III or IV congestive heart failure, according to the New York Heart Association)\n* History or suspected demyelinating disease of the central nervous system, e.g. multiple sclerosis or optic neuritis\n* Current participation in clinical trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Synovial TNFa, CXCL13, IL-8, IL-6, IL-1b, IL-10, IP-10, BCL3, CD3E, DUSP4, FOXP3, CD79A, CD138, MMP-3, and MMP-1 After 12 Weeks of Treatment With Certolizumab Pegol (CZP) in Patients With Rheumatoid Arthritis","description":"Synovial tissue biopsy samples were taken at baseline and at 12 weeks after starting treatment with CZP. These samples were analyzed to determine the concentrations of select biomarkers and to determine the percent change in concentration from baseline to week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Screening in Disease Activity Score (DAS) 28 ESR After 14 Weeks of Treatment","description":"The DAS 28 ESR is a score calculated from the results of a 28-count joint assessment (total number of tender joint possible is 28, and total number of swollen joints possible is 28), the Erythrocyte Sedimentation Rate (ESR), and the Patient Global Assessment (measured using a 100 mm visual analogue scale, with the lowest possible score of 0 mm meaning the subject is not affected at all by arthritis and the highest possible score of 100 mm meaning the subject is severely affected by arthritis). A lower DAS 28 ESR indicates less active disease, and a higher DAS 28 ESR indicates more active disease. The DAS 28 ESR was calculated for each subject at the screening visit and at the Week 14 final visit. The percent change was then calculated for each patient, and a mean percent change for all subjects was determined.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.5","spread":"25.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Upper respiratory infection","Headache","Rash","Injection site reaction","Flare of Rheumatoid Arthritis"]}}}